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Objective: The objective of this study was to determine serum advanced glycation end products (AGEs) levels in black South 
African patients with and without type 2 diabetes (T2D) and to compare the results with those reported for other ethnic/race 
groups.
Design: Analytical cross-sectional study.
Setting and subjects: The study subjects consisted of 138 black South African patients with
T2D and 81 non-diabetic patients at Dr George Mukhari Academic Hospital in Pretoria, South Africa.
Outcome measures: Serum total AGEs (TAGEs), Nɛ-carboxymethyl-lysine (CML), Nɛ-carboxyethyl-lysine (CEL) and fluorescent 
AGEs (FAGEs).
Results: Serum TAGEs, CML and CEL levels but not FAGEs were significantly higher in T2D patients than in non-diabetic patients. 
Serum TAGEs were lower than those reported for other ethnic/race groups whereas CML and FAGEs were within ranges reported 
for other ethnic/race groups. Only serum CEL levels were significantly higher in male than in female T2D patients and only serum 
FAGEs levels were negatively associated with age of the study subjects.
Conclusions: With the exception of FAGEs, serum AGEs levels are significantly higher in T2D than in non-diabetic black South 
Africans patients. Also, serum TAGE levels black South African appear to be lower than those reported for other ethnic/race 
groups.
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Introduction
Advanced glycation end products (AGEs) are a heterogeneous 
group of compounds formed by the non-enzymatic reactions of 
proteins, lipids or nucleic acids with reducing sugars as part of the 
so-called ‘Maillard reaction’.1,2 AGEs accumulate gradually with 
age on long-lived protein such as collagen, but are formed at a 
more rapid rate in conditions associated with hyperglycaemia 
and oxidative stress such as diabetes mellitus.2,3 AGEs are 
implicated in the development and progression of both 
microvascular complications (nephropathy, retinopathy and 
neuropathy) and macrovascular complications (myocardial 
infarction, stroke and peripheral artery disease) of diabetes.3–6 It 
has been established that AGEs contribute to the development of 
vascular complications of diabetes mellitus through binding and 
cross-linking of both intracellular and extracellular matrix proteins 
as well as through the modulation of cellular function via binding 
to the receptor for advanced glycation end products (RAGE).6,7
Twin studies and comparison studies of different ethnic groups 
suggest that both circulating and tissue AGE levels may be 
genetically determined. In this regard, Leslie et al.8 investigated 
whether genetic factors influence serum levels of Nɛ-
carboxymethyl-lysine (CML), the most abundant circulating AGE in 
monozygotic and dizygotic twin pairs living under different 
environmental conditions and found that twin correlations for 
serum CML levels were significantly higher in monozygotic twin 
pairs (r = 0.71) than in dizygotic twin pairs. In support of the notion 
that tissue AGE levels may also be genetically determined, studies 
that have measured and compared tissue AGE levels among 
Caucasians, African Americans, Chinese, Arabs and South Asians 
have reported that skin-fluorescent AGE levels are higher among 
Caucasian groups compared with that in African Americans9 and 
Chinese, as well as higher in Arabs compared with South Asians.10 
Although the genes responsible for the above-mentioned racial 
variations in both serum and tissue AGE levels are still unknown, it 
has been hypothesised that genetic polymorphism of the enzyme 
glyoxylase I that is involved in the degradation of some AGEs and 
their precursors in vivo may play a role in this regard.11 Also, 
differences in diet and the way food is prepared among different 
ethnic groups may contribute to the observed racial differences in 
both circulating and tissue AGE levels.12 To the best knowledge of 
the authors there are no  published studies that have investigated 
and reported on circulating AGE levels among black African 
individuals and compared these with levels reported for other 
ethnic groups. Thus, the aim of the current study was to measure 
serum levels of the major types of circulating AGEs in black South 
African patients with and without diabetes, and to compare these 
with those measured in other ethnic groups using similar 
measurement techniques.
Study design and methods
Study design
The study was an analytical cross-sectional study.
Setting
The study was conducted at Dr George Mukhari Academic 
Hospital (DGMAH), a tertiary hospital near Pretoria, South Africa, 
that caters for mostly black African patients and serves as a 
training site for the Faculty of Health Sciences of the Sefako 
Makgatho Health Sciences University (formally the Medunsa 
campus of the University of Limpopo).
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Subjects
In total, 138 subjects with type 2 diabetes (T2D) and 81 control 
subjects were randomly recruited into the study. Patients were 
excluded from the study if they had evidence of renal disease. All 
study subjects gave their informed consent after the aim of the 
study and their rights were fully explained to them. The control 
group was a convenience sample of patients with no history of 
diabetes that were admitted to orthopaedic wards at DGMAH. 
This group of patients was asked to fast overnight before blood 
samples were collected for the measurement of fasting plasma 
glucose, urea and creatinine. Only patients with FPG < 6.1 mmol/L, 
and estimated GFR > 60 ml/min were included in the final control 
sample. The study was conducted in accordance with the 
requirements of the research and ethics committee of the 
University of Limpopo (MREC/P/201/2013:PG).
Measurements
Body weight in light clothing was measured using a calibrated 
digital electronic scale, to the nearest 0.1 kg. Height was recorded 
to the nearest 0.5  cm using a wall-mounted stadiometer. Body 
mass index (BMI) was calculated as weight divided by height in 
metres squared (kg/m²). Blood pressure was measured with a 
blood pressure machine (EDAN Vital Signs Monitor®, model M3A 
(Dieckhoff & Ratschow Praxisdienst GmbH, Longuich, Germany) 
in a sitting position after the subject had rested for about 10 min. 
After an overnight fast, venous blood samples for the 
measurement of serum AGEs, lipid parameters, urea and 
creatinine were collected from all participants into blood 
collection tubes (BD Vacutainer®, Franklin Lakes, NJ, USA), and left 
to clot for 30 min and centrifuged at 4000 rpm for 15 min at 4°C. 
The resultant serum samples were then aliquotted and stored at 
-80 °C until analysed. For blood glucose and glycated haemoglobin 
(HbA1c) measurements blood samples were collected into citrate 
and EDTA blood tubes respectively. Serum total AGEs (TAGEs), 
CML and Nɛcarboxyethyl-lysine (CEL) were measured respectively 
using STA-317, STA-316 and STA-300 OxiselectTM ELISA kits 
(2BScientific, Upper Heyford, UK) according to the manufacturer’s 
instructions. Fluorescent serum AGEs (FAGEs) were measured 
according to the method described by Münch et al.13 In brief, 20 μl 
of serum was diluted to a volume of 10 ml with 20 mM phosphate 
buffered saline; pH 7.4. Fluorescence of the diluted sample was 
then measured spectrofluorometrically (excitation at 370 nm and 
emission at 440  nm) using a GloMax® Multi detection 
spectrofluorometer (Promega Corp, Madison, WI, USA). 
Fluorescent readings were expressed as arbitrary units (emission 
intensity/excitation intensity).
Fasting blood glucose, total cholesterol, triglycerides, high-
density lipoprotein cholesterol, urea and creatinine were 
measured using commercially available kits adapted to the 
Beckman Coulter UniCel DXC 800 Synchron® Clinical System 
(Johannesburg, SA) available in the National Health Laboratory 
Services (NHLS) laboratory at the DGMAH. LDL-C was calculated 
from Friedwald’s formula. HbA1c was measured using the 
immune chemiluminescent assay kit adapted to the Abbot 
Architect system Ci 8200® (Abbott Diagnostics Division, 
Johannesburg, SA) in the NHLS laboratory at DGMAH in 
accordance with the manufacturer’s instructions.
Statistical analysis
Demographic and clinical data were expressed as mean ± SD and 
compared between T2D and non-diabetic patients using the 
Student t-test for independent samples. Distributions of the 
different types of serum AGEs were expressed in terms of whisker 
box plots as median (interquartile range) and compared between 
T2D and non-diabetic patients as well as between male and 
female T2D patients using the non-parametric Mann–Whitney U 
test. The Spearman rank correlation coefficient was used to 
determine correlations among the different study parameters. p-
values of less than 0.05 were considered statistically significant. 
All statistical analysis and distributions were performed using 
SPSS version 23® software (IBM Corp, Armonk, NY, USA).
Results
Demographic and clinical characteristics of study 
subjects
Demographic and clinical characteristics of the T2D and non-
diabetic patients are summarised in Table 1. Subjects with T2D 
had significantly higher HbA1c, fasting plasma glucose, BMI, and 
systolic blood pressure than the control group (p < 0.05). Mean 
HbA1c values were: 9.65  ±  1.18% (81  ±  0.99  mmol/mol) vs. 
6.1 ± 2.6% (43 ± 5 mmol/l) (p < 0.05). Also, serum lipids did not 
differ between the T2D and control subjects. Some 86.2% of T2D 
study subjects had poor glycaemic control. The duration of T2D 
was more than 10 years in 42.0% of the T2D study subjects and 
was less than 10  years in 58.0% of the study subjects. Almost 
equal proportions of T2D subjects were treated with oral 
hypoglycaemic agents (OHAs) only or OHAs plus insulin (49.3% 
versus 50.7% respectively) (see Table 1).
Table 1: Demographic and clinical characteristics of T2D study subjects 
and control
Notes: FBG = fasting blood glucose; LDL = low-density lipoprotein; HDL = 
high-density lipoprotein; HbA1c = haemoglobin A1c; SBP = systolic blood 
pressure; DBP = diastolic blood pressure; GFR = glomerular filtration rate; 
BMI = body mass index; TC = total cholesterol.
Characteristic T2D group Non-diabetic 
control group
p-value
(n = 138) (n = 83)
Mean ± SD Mean ± SD
Age (years) 56.9 ± 9.4 51.1 ± 9.8 0.152
FPG (mmol/L) 11.6 ± 3.3 5.2 ± 6.3 0.012
HbA1c (%) 9.7 ± 1.2 6.1 ± 2.6 0.037
HbA1c (mmol/mol) 81 ± 0.99 43 ± 5 0.037
BMI (kg/m²) 31.6 ± 4.7 26.8 ± 5.5 0.031
TC (mmol/L) 4.70 ± 1.80 4.23 ± 0.95 0.174
HDL (mmol/L) 1.1 ± 0.3 1.08 ± 5.5 0.416
LDL (mmol/L) 2.5 ± 0.15 2.1 ± 0.2 0.511
Triglyceride (mmol/L) 1.2 ± 0.5 1.32 ± 0.4 0.712
SBP (mmHg) 157 ± 16.9 138 ± 11.7 0.041
DBP (mmHg) 85 ± 10.8 84 ± 8.4 0.091
Urea (mmol/L) 6.0 ± 2.5 5.6 ± 1.3 0.421
Creatinine (μmol/L) 94 ± 55.9 86.4 ± 21.1 0.408
GFR (ml/min/1.73m2) 101.6 ± 22.4 95.7 ± 23.1 0.116
Poor diabetic control 
(HbA1c > 7.0%), n (%) 119 (86.2) – –
Duration of diabetes  
(< 10 years), n (%) 80 (58.0) – –
Duration of diabetes  
(> 10 years), n (%) 58 (42.0) – –
Oral hypoglycaemic 
agents only, n (%) 68 (49.3) – –
Oral hypoglycaemic 
agents + insulin, n (%) 70 (50.7) – –
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Comparison of serum AGE levels of diabetic and 
non-diabetic study subjects
Box-plot distributions of serum levels of the different types of 
measured AGEs in T2D and non-diabetic patients after removal 
of outliers are shown in Figure 1. Serum TAGEs, CML and CEL 
levels of T2D patients were positively skewed whereas those of 
the non-diabetic patients were symmetrically distributed. 
Serum FAGEs levels of both T2D and non-diabetic patients 
groups were also positively skewed. With the exception of 
FAGEs the interquartile range (IQR) of all the measured serum 
AGEs were larger in the T2D group than in the non-diabetic 
patient group. Serum TAGEs, CML and CEL levels were 
significantly higher in the T2D patient group compared with the 
non-diabetic patient group; median (IQR) were 0.21 (0.18–0.58) 
vs. 0.16 (0.15–0.17) μg/mL, p = 0.0001; 47.5 (16.6–91.7) vs. 22.6 
(2.2–47.4) ng/mL, p = 0.0001; and 27.2 (23.2–43.6) vs. 23.1 (20.2–
26.8) ng/mL, p  =  0.001, respectively. On the other hand there 
was no significant difference between serum FAGEs levels of the 
(a) (b)
(c) (d)
Figure 1: Comparison of serum levels of (A) total AGEs (TAGEs), (B) Nɛ-carboxymethyl-lysine (CML), (C) Nɛ-carboxyethyl-lysine (CEL) and (D) fluorescent 
AGEs (FAGEs) between type 2 diabetic and non-diabetic black South African patients. AU = arbitrary units.
(a) (b)
(c) (d)
Figure 2: Comparison of serum levels of (A) total immunogenic AGEs (TIAGEs), (B) carboxymethyl-lysine (CML), (C) carboxyethyl-lysine (CEL) and (D) 
fluorescent AGEs (FAGEs) between male and female black South African type 2 diabetic patients.
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T2D patient group and that of the non-diabetic patient group; 
median (IQR), 94.2 (88.4–109) AU versus 88.9 (86.5–120) AU 
(p = 0.149).
Comparison of serum AGE levels of male and female 
diabetic subjects
Levels of the different types of serum AGEs measured in the T2D 
study subjects were stratified by gender and compared in order to 
determine whether serum AGE levels are influenced by gender. The 
results shown in Figure 2 indicate that with the exception of median 
CEL level, which was significantly higher in male than in female 
diabetic subjects (median [IQR], 27.2 [23.2–43.6] vs. 23.1 [20.2–26.8] 
ng/mL, p = 0.001); no significant differences between median TAGE, 
CML and FAGE levels of male and female diabetic study subjects 
(p = 0.717, 0.087 and 0.993 respectively) were observed.
Table 2a: Correlations between serum AGEs and BMI, age of the study subjects, lipids/lipoproteins as well as HbA1c among the non-diabetic control 
subjects
Notes: TAGEs = total AGEs; CEL = varboxyethyl-lysine; LDL-C = low-density cholesterol; CML = carboxymethyl-lysine; FAGEs = fluorescent AGEs; HDL-C = 
high-density cholesterol; rs = Spearman’s correlation coefficient; BMI = body mass index; TRIGs = triglycerides; HbA1c = glycated haemoglobin.
*Significant at the 0.05 level (1-tailed).
Factor BMI Age of subjects LDL-C HDL-C TRIGs HbA1c
TAGEs
rs −0.081 0.302 0.004 0.312* 0.120 −0.115
p (1-tail) 0.331 0.671 0.131 0.031 0.071 0.062
CML
rs 0.037 0.029 −0.117 0.063 −0.107 0.121
p (1-tail) 0.251 0.132 0.151 0.350 0.111 0.051
CEL
rs 0.171 −0.013 −0.169* −0.011 0.062 0.081
p (1-tail) 0.118 0.340 0.021 0.410 0.413 0.568
FAGEs
rs 0.173 0.313* −0.258* 0.028 0.225* 0.104
p (1- tail) 0.210 0.044 0.025 0.244 0.031 0.094
Table 2b: Correlations between AGEs and BMI, duration of diabetes, age of the study subjects lipids/lipoproteins as well as HbA1c among the diabetic 
study subjects
Notes: TAGEs = total AGEs; CEL = carboxyethyl-lysine; LDL-C = low-density cholesterol; CML = carboxymethyl-lysine; FAGEs = fluorescent AGEs; 
LDL-C = low-density cholesterol; r = Spearman’s correlation coefficient; BMI = body mass index; HDL-C = high-density cholesterol; HbA1c = glycated 
haemoglobin.
#p-value for comparison of rs with that of the non-diabetic control group.
*Significant at the 0.05 level (1-tailed).
Factor BMI Duration of diabetes Age of subjects LDL-C HDL-C TRIGs HbA1c
TAGEs
rs −0.041 −0.232* 0.146 0.041 0.342* 0.210 −0.251
p (1-tail) 0.374 0.034 0.358 0.400 0.015 0.094 0.057
 p (1-tail)# 0.413 – 0.018* 0.421 0.180 0.308 0.221
CML
rs .071 −0.005 0.179 −0.177 0.083 −0.198 0.171
 p (1-tail) 0.285 0.483 0.410 0.135 0.305 0.107 0.097
p (1-tail)# 0.190 – 0.830 0.371 0.305 0.288 0.274
CEL
rs .160 −0.076 0.183 −0.289* −0.008 0.005 0.100
 p (1-tail) 0.103 0.278 0.460 0.033 0.481 0.488 0.094
p (1-tail)# 0.476 – 0.173 0.251 0.492 0.265 0.444
FAGEs
rs −.073 0.085 −0.243* −0.285* 0.031 0.265* 0.174
p (1- tail) 0.280 0.254 0.024 0.030 0.422 0.041 0.094
p (1-tail)# 0.291 – 0.034* 0.436 0.492 0.087 0.492
Table 3a: Correlation of the different types of serum AGEs measured in 
the non-diabetic control group with one another
Note: rs: Spearman correlation coefficient.
**Significant at the 0.01 level (1-tailed).
Factor TAGEs CML CEL FAGEs
TAGEs
rs 1.00 0.665** −0.194 0.385
p (1-tail) 0.000 0.080 0.091
CML
rs 0.665** 1.00 0.350** 0.209
p (1-tail) 0.00 0.000 0.101
CEL
rs −0.194 350** 1.00 0.102
p (1-tail) 0.080 0.000 0.214
FAGEs
rs 0.385 0.209 0.102 1.00
p (1-tail) 0.091 0.101 0.214
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study subjects
Notes: TAGEs = total AGEs; CEL = carboxyethyl-lysine; LDL-C = low-density cholesterol; CML = carboxymethyl-lysine; FAGEs = fluorescent AGEs; 
LDL-C = low-density cholesterol; r = Spearman’s correlation coefficient; BMI = body mass index; HDL-C = high-density cholesterol; HbA1c = glycated 
haemoglobin.
#p-value for comparison of rs with that of the non-diabetic control group.
*Significant at the 0.05 level (1-tailed).
Factor BMI Duration of diabetes Age of subjects LDL-C HDL-C TRIGs HbA1c
TAGEs
rs −0.041 −0.232* 0.146 0.041 0.342* 0.210 −0.251
p (1-tail) 0.374 0.034 0.358 0.400 0.015 0.094 0.057
 p (1-tail)# 0.413 – 0.018* 0.421 0.180 0.308 0.221
CML
rs .071 −0.005 0.179 −0.177 0.083 −0.198 0.171
 p (1-tail) 0.285 0.483 0.410 0.135 0.305 0.107 0.097
p (1-tail)# 0.190 – 0.830 0.371 0.305 0.288 0.274
CEL
rs .160 −0.076 0.183 −0.289* −0.008 0.005 0.100
 p (1-tail) 0.103 0.278 0.460 0.033 0.481 0.488 0.094
p (1-tail)# 0.476 – 0.173 0.251 0.492 0.265 0.444
FAGEs
rs −.073 0.085 −0.243* −0.285* 0.031 0.265* 0.174
p (1- tail) 0.280 0.254 0.024 0.030 0.422 0.041 0.094
p (1-tail)# 0.291 – 0.034* 0.436 0.492 0.087 0.492
Table 3a: Correlation of the different types of serum AGEs measured in 
the non-diabetic control group with one another
Note: rs: Spearman correlation coefficient.
**Significant at the 0.01 level (1-tailed).
Factor TAGEs CML CEL FAGEs
TAGEs
rs 1.00 0.665** −0.194 0.385
p (1-tail) 0.000 0.080 0.091
CML
rs 0.665** 1.00 0.350** 0.209
p (1-tail) 0.00 0.000 0.101
CEL
rs −0.194 350** 1.00 0.102
p (1-tail) 0.080 0.000 0.214
FAGEs
rs 0.385 0.209 0.102 1.00
p (1-tail) 0.091 0.101 0.214
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subjects, a significant positive correlation was observed only 
between CML and CEL (p < 0.01) (Table 3b). When the correlation 
coefficients obtained amongst the measured serum AGEs in 
diabetic subjects were compared with those obtained amongst 
the measured serum AGEs in the non-diabetic control group, 
significant differences were observed between CML with TAGEs 
(p < 0.01), between CEL with TAGEs (p < 0.05) and between CML 
with CEL (p < 0.05).
Discussion
The current study has several main findings. First, as expected, 
significant differences were observed between some biochemical 
and clinical parameters of T2D patients and those of the non-
diabetic patients. Second, there were significant differences in 
serum levels of TAGEs, CML and CEL but non-significant difference 
in serum levels of FAGEs between T2D and the non-diabetic 
patient groups. Third, only serum CEL levels were found to be 
significantly higher in male than in female T2D study subjects. 
Fourth, serum levels of FAGEs appeared to increase with 
increasing age in the non-diabetic control group and appeared to 
decrease with increasing age in T2D study subjects. Also, there 
were mixed associations between several serum AGEs and lipid/
lipoprotein parameters as well as among some types of serum 
AGEs in both non-diabetic control and diabetic study subjects. 
Fifth, when correlations between serum AGEs measured in 
diabetic subjects and BMI, age of the study subjects, HbA1c as 
well as lipid/lipoprotein parameters were compared with those 
between serum AGEs measured in non-diabetic subjects and 
similar parameters, significant differences were observed for the 
correlations between FAGEs, TAGEs and age of the study subjects. 
Lastly, significant differences were observed between CML with 
TAGEs as well as between CML with CEL when correlation 
coefficients among the measured serum AGEs were compared 
between T2D subjects and non-diabetic controls.
As expected, biochemical indicators of glycaemic control (FBG 
and HbA1c) were found to be significantly higher in T2D study 
subjects compared with the non-diabetic control group. This 
observation can be attributed to a number of factors including: 
loss of glucose tolerance associated with the diabetic state, 
treatment non-compliance or failure as well as presence of 
determinants of poor glycaemic control such as obesity.14,15 
Serum levels of TAGEs, CML and CEL were found to be significantly 
higher in the T2D patient group compared with the non-diabetic 
patient group. These results, however, could not be compared 
with the results of other published studies, as subjects in these 
studies were in different environments and probably consumed 
different types of diets.
Unexpectedly, serum FAGE levels of T2D patients were not 
significantly different from those of non-diabetic patients. This 
observation might be attributed to the nature of the control 
group used in the current study. High serum AGE levels, in 
particular high serum level of pentosidine, the most abundant 
fluorescent AGE in plasma and tissues, have been associated with 
the development and progression of osteoporosis in diabetic and 
non-diabetic menopausal women.16–18 Whether the high level of 
pentosidine observed in the cited studies is the cause or product 
of osteoporosis is currently not clear. It is possible that our patient 
control group, which was recruited from orthopaedic wards at 
DGMAH, may have included non-diabetic postmenopausal 
women with osteoporosis-related fractures. While this likelihood 
was not verified in the current study, it might explain the observed 
discrepancy between the results of the current study and those of 
similar previous studies with regard to the level of FAGEs.
Correlations between BMI, duration of diabetes, 
age of the study subjects, lipids/lipoproteins and 
different types of serum AGEs in diabetic subjects
Factors known to be associated with poor glycaemic control such 
as BMI, duration of diabetes, age of the study subjects and lipid/
lipoprotein levels were correlated with the different types of AGEs 
measured in the current study using the Spearman correlation 
coefficient (rs). Results for the correlations of serum AGEs 
measured in non-diabetic control and T2D diabetic subjects are 
presented in Tables 2a and 2b respectively. As shown in Table 2a, 
for serum AGEs measured in non-diabetic control subjects, 
significant positive correlations were observed between TAGEs 
and HDL-C (p < 0.05) between FAGEs and TRIGs (p < 0.05) as well 
as between FAGEs and age of the study subjects (p  <  0.05). 
Significant negative correlations were observed between CEL and 
LDL-C (p < 0.05) and between FAGEs and LDL-C (p < 0.05). For the 
serum AGEs measured in diabetic subjects, significant positive 
correlations were observed between TAGEs and HDL-C as well as 
between FAGEs and TRIGs (p  <  0.05) (Table 2b). Significant 
negative correlations were observed between FAGEs and age of 
the study subjects, between TAGEs and duration of diabetes as 
well as between FAGEs and LDL-C (p < 0.05). In the current study, 
Spearman correlation coefficients obtained for the association 
between serum AGEs and BMI, age of the study subjects as well as 
lipid/lipoprotein parameters were compared with those obtained 
for the non-diabetic control group. In this regard, significant 
differences were observed between correlation coefficients of 
TAGEs and age of the study subjects as well as between FAGEs 
and age of the study subjects (p < 0.05) (Table 2b).
Correlation of the different types of serum AGEs with 
one another
The current study also investigated whether there were significant 
correlations among the different types of AGEs measured in the 
blood sera of the non-diabetic control group as well as those 
measured among the diabetic group. Results of these objectives 
are presented in Tables 3a and 3b respectively. As shown in Table 
3a, among the serum AGEs measured in the non-diabetic control 
group, significant positive correlations were observed between 
CML and TAGEs (p  <  0.01), as well as between CML and CEL 
(p  <  0.01). Amongst the serum AGEs measured in diabetic 
Table 3b: Correlation of the different types of serum AGEs measured in 
diabetic subjects with one another
*Significant at the 0.05 level (1-tailed).
**Significant at the 0.01 level (1-tailed).
#p-value for comparison of rs with that of the non-diabetic control group.
Factor TAGEs CML CEL FAGEs
TAGEs
rs 1.00 0.160 0.191 0.002
p (1-tail) 0.100 0.063 0.491
p (1-tail)# 0.000** 0.017* 0.097
CML
rs 0.160 1.00 0.597** 0.166
p (1-tail) 0.100 0.000 0.101
p (1-tail)# 0.000** 0.039* 0.405
CEL
rs 0.191 0.597** 1.00 0.090
p (1-tail) 0.063 0.000 0.248
p (1-tail)# 0.017* 0.039* 0.472
FAGEs
rs 0.002 0.166 0.090 1.00
p (1-tail) 0.491 0.101 0.248
p (1-tail)# 0.097 0.405 0.472
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measured AGEs and HbA1c in both T2D subjects and non-diabetic 
control subjects. An explanation that has been brought forward 
for this lack of association is the fact that AGEs can also be formed 
through other metabolic pathways beside glucose metabolic 
pathways; for example CML can be formed from oxidation of 
lipids.2,20 Moreover, HbA1c and AGEs presumably reflect different 
pathways following hyperglycaemia and different duration of 
hyperglycaemia.
Currently serum AGEs are not routinely measured in most clinical 
laboratories, thus the result of this study may go a long way in 
raising awareness of the need to measure and monitor their levels 
in diabetic patients. Furthermore, as AGEs are involved in the 
development and progression of vascular complications of 
diabetes, their measurement and pharmacological intervention 
could help in the prevention of long-term complications of 
diabetes.
Limitations of the study
There are several limitations that should be taken into 
consideration when interpreting results of the current study. First, 
the sample size was small and study subjects were recruited from 
a single health institution, thus the findings could not be 
generalised beyond the study samples. Second, the current study 
is a cross-sectional study and therefore cause-and-effect 
relationships could not be inferred from the study results. Third, 
the possible confounding effect of exogenous dietary and 
smoking-related AGEs on serum AGE levels was not addressed in 
this study. Fourth, the control group selected for this study might 
have confounded the results, particularly those for the FAGEs. 
Lastly, the current study did not concurrently measure serum 
levels of AGEs for other South African race groups for comparison 
purposes. Despite these limitations, the authors believe that the 
results of this study are of great interest in that they are the first to 
describe the status of serum AGE levels among black South 
African T2D subjects.
Conclusions
The results of the current study suggest that serum AGE levels are 
significantly higher in T2D than in non-diabetic black South Africans, 
and with the exception of CEL are not influenced by gender. Also, 
serum FAGE levels appear to be positively associated with increasing 
age of study subjects in non-diabetic controls, but not in T2D 
subjects. In addition, the current study has revealed significant 
associations between various serum AGE levels and lipid/lipoprotein 
parameters as well as among the different types of serum AGEs and 
no significant association between serum AGEs and glycated 
haemoglobin among South African black patients with T2D.
References
1.  Tessier FJ. The maillard reaction in the human body. The main 
discoveries and factors that affect glycation. Pathol Biol. 2010;58:214–9. 
http://dx.doi.org/10.1016/j.patbio.2009.09.014
2.  Vistoli G, De Maddis D, Cipak A., et al. Advanced glycoxidation and 
lipoxidation end products (AGEs and ALEs): an overview of their 
mechanisms of formation. Free Radic Res. 2013;47(sup1):3–27. 
http://dx.doi.org/10.3109/10715762.2013.815348
3.  Singh VP, Bali A, Singh N, et al. Advanced glycation end products and 
diabetic complications. Korean J Physiol Pharmacol. 2013;18:1–14.
4.  Nin JW, Jorsal A, Ferreira I, et al. Higher plasma levels of 
advanced glycation end products are associated with incident 
cardiovascular disease and all-cause mortality in type 1 diabetes: 
a 12-year follow-up study. Diabetes Care. 2011;34:442–7. 
http://dx.doi.org/10.2337/dc10-1087
5.  Goh S-Y, Cooper ME. The role of advanced glycation end products in 
progression and complications of diabetes. J Clin Endocrinol Metab. 
2008;93:1143–52. http://dx.doi.org/10.1210/jc.2007-1817
The current study also investigated the effect of gender of T2D 
study subjects as well as of the age of both diabetic and non-
diabetic subjects on levels of the different types of serum AGEs. 
Whereas there were no significant differences between serum 
TAGEs, CML and FAGEs for male compared with female T2D 
subjects, serum CEL levels were found to be significantly higher in 
males compared with female T2D subjects (p < 0.01). A possible 
explanation for this observation, which has never been reported 
before, may be the fact that, unlike the other types of AGEs, which 
are produced by multiple metabolic pathways and precursors, 
CEL is mainly produced by the glycolytic–methylglyoxal pathway.2 
It is thus possible that gender-specific hormones may influence 
the synthesis of CEL in a unique way.
Previous studies have shown that tissue levels of AGEs, in particular 
skin FAGEs, increase with age of the study subjects.10,13 In the 
current study, there was no association between serum levels of 
AGEs, CML and CEL with age of both T2D and non-diabetic study 
subjects. However, a decrease in serum levels of FAGEs with 
increasing age of T2D patients and an increase in serum levels of 
FAGEs with increasing age of the control group was observed in 
the current study. The observation that serum FAGEs of the control 
group increased with increased age could also be attributed to the 
nature of the control group as explained above.
The observed significant negative associations between various 
serum AGEs and lipid/lipoprotein parameters cannot readily be 
explained, but the significant positive association observed 
between a number of serum AGEs and lipid/lipoprotein 
parameters could be attributed to the fact that some AGEs are 
known to be derived from lipid and lipoprotein oxidation.2,3 
Furthermore, the observed significant differences in the 
correlation coefficients between serum AGEs measured in 
diabetic patients and those measured in non-diabetic subjects 
could be attributed to the effect of hyperglycaemia on the 
formation of AGEs.2,3
Different types of circulating AGEs are described in the literature,2,3 
and whereas some AGEs such as CML, CEL, pentosidine and 
hydroimidazolones are immunogenic and can be measured using 
immunochemical methods, others such as pentosidine are both 
immunogenic and fluorescent and can also be measured using 
spectrofluorometric techniques.13 In the current study we 
measured TAGEs by means of an ELISA with a polyclonal primary 
antibody directed against CML, pentosidine and other non-
specified AGEs. Serum CML and CEL were measured by ELISA with 
monoclonal antibodies directed against their antigenic epitopes 
whereas FAGEs were measured spectrofluorometrically. When the 
results of these different measurement techniques were 
correlated with one another, significant positive correlations were 
observed between CML and TAGEs (p < 0.01) as well as between 
CML and CEL (p < 0.05). Whereas the former finding was expected 
due to the fact that CML is the major epitope for the polyclonal 
antibody used in the measurement of TAGEs, the latter finding 
was not expected due to the fact that CEL and CML are generally 
known to be produced by separate metabolic pathways.2 To the 
best knowledge of the authors, the current study is the first to 
investigate the correlations among different serum AGEs in both 
T2D subjects and non-diabetic control subjects.
Previous studies that have investigated and reported on the 
association between serum AGE levels and HbA1c found weak or 
no correlation between serum AGE levels and HbA1c.19,20 In 
agreement with these previous studies, the current study found 
weak non-significant correlations between the serum levels of 
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through other metabolic pathways beside glucose metabolic 
pathways; for example CML can be formed from oxidation of 
lipids.2,20 Moreover, HbA1c and AGEs presumably reflect different 
pathways following hyperglycaemia and different duration of 
hyperglycaemia.
Currently serum AGEs are not routinely measured in most clinical 
laboratories, thus the result of this study may go a long way in 
raising awareness of the need to measure and monitor their levels 
in diabetic patients. Furthermore, as AGEs are involved in the 
development and progression of vascular complications of 
diabetes, their measurement and pharmacological intervention 
could help in the prevention of long-term complications of 
diabetes.
Limitations of the study
There are several limitations that should be taken into 
consideration when interpreting results of the current study. First, 
the sample size was small and study subjects were recruited from 
a single health institution, thus the findings could not be 
generalised beyond the study samples. Second, the current study 
is a cross-sectional study and therefore cause-and-effect 
relationships could not be inferred from the study results. Third, 
the possible confounding effect of exogenous dietary and 
smoking-related AGEs on serum AGE levels was not addressed in 
this study. Fourth, the control group selected for this study might 
have confounded the results, particularly those for the FAGEs. 
Lastly, the current study did not concurrently measure serum 
levels of AGEs for other South African race groups for comparison 
purposes. Despite these limitations, the authors believe that the 
results of this study are of great interest in that they are the first to 
describe the status of serum AGE levels among black South 
African T2D subjects.
Conclusions
The results of the current study suggest that serum AGE levels are 
significantly higher in T2D than in non-diabetic black South Africans, 
and with the exception of CEL are not influenced by gender. Also, 
serum FAGE levels appear to be positively associated with increasing 
age of study subjects in non-diabetic controls, but not in T2D 
subjects. In addition, the current study has revealed significant 
associations between various serum AGE levels and lipid/lipoprotein 
parameters as well as among the different types of serum AGEs and 
no significant association between serum AGEs and glycated 
haemoglobin among South African black patients with T2D.
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